These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 16460787)

  • 1. The role of maintenance therapy and novel taxanes in ovarian cancer.
    Herzog TJ; Coleman RL; Markman M; Cella D; Thigpen JT
    Gynecol Oncol; 2006 Aug; 102(2):218-25. PubMed ID: 16460787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.
    Kyrgiou M; Salanti G; Pavlidis N; Paraskevaidis E; Ioannidis JP
    J Natl Cancer Inst; 2006 Nov; 98(22):1655-63. PubMed ID: 17105988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer.
    Muggia FM
    Semin Oncol; 2004 Dec; 31(6 Suppl 15):19-24. PubMed ID: 15726535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer.
    Eichbaum MH; Weiss LM; Bruckner T; Schneeweiss A; Sinn HP; Gebauer G; Fersis N; Kussmaul J; Sohn C
    Med Sci Monit; 2009 Apr; 15(4):CR156-63. PubMed ID: 19333199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
    Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taxanes in the adjuvant treatment of early breast cancer, emerging consensus and unanswered questions.
    Tang SC
    Cancer Invest; 2009 Jun; 27(5):489-95. PubMed ID: 19479486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.
    Marsh S; Paul J; King CR; Gifford G; McLeod HL; Brown R
    J Clin Oncol; 2007 Oct; 25(29):4528-35. PubMed ID: 17925548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
    Piccart-Gebhart MJ; Burzykowski T; Buyse M; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
    J Clin Oncol; 2008 Apr; 26(12):1980-6. PubMed ID: 18421049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study.
    ; Secord AA; Lee PS; Darcy KM; Havrilesky LJ; Grace LA; Marks JR; Berchuck A
    Gynecol Oncol; 2006 Jun; 101(3):390-7. PubMed ID: 16551475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment.
    Vici P; Viola G; Rossi S; Botti C; Vitucci C; Sergi D; Ferranti FR; Saracca E; Di Lauro L; Corsetti S; Foggi P; Fattoruso SI; Lopez M
    Clin Ter; 2008; 159(6):453-6. PubMed ID: 19169608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unresolved issues in the chemotherapeutic management of gynecologic malignancies.
    Markman M
    Semin Oncol; 2006 Apr; 33(2 Suppl 6):S33-8. PubMed ID: 16716801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.
    Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Aghajanian C; Barakat RR; Chi DS
    Gynecol Oncol; 2008 Feb; 108(2):276-81. PubMed ID: 18063020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study.
    Wenzel LB; Huang HQ; Armstrong DK; Walker JL; Cella D;
    J Clin Oncol; 2007 Feb; 25(4):437-43. PubMed ID: 17264340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
    Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
    J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraperitoneal chemotherapy for ovarian cancer.
    Hamilton CA; Berek JS
    Curr Opin Oncol; 2006 Sep; 18(5):507-15. PubMed ID: 16894301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care.
    Fung-Kee-Fung M; Provencher D; Rosen B; Hoskins P; Rambout L; Oliver T; Gotlieb W; Covens A;
    Gynecol Oncol; 2007 Jun; 105(3):747-56. PubMed ID: 17368522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside.
    de Bree E; Theodoropoulos PA; Rosing H; Michalakis J; Romanos J; Beijnen JH; Tsiftsis DD
    Cancer Treat Rev; 2006 Oct; 32(6):471-82. PubMed ID: 16942841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
    Fotopoulou C; duBois A; Karavas AN; Trappe R; Aminossadati B; Schmalfeldt B; Pfisterer J; Sehouli J;
    J Clin Oncol; 2008 Jun; 26(16):2683-9. PubMed ID: 18509180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience.
    Leiser AL; Chi DS; Ishill NM; Tew WP
    Gynecol Oncol; 2007 Jun; 105(3):657-61. PubMed ID: 17395252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.